Hints and tips:
...The increase had “made it unviable for Celltrion to continue to supply medicines to the NHS”, he wrote....
...Celltrion plans to later this month announce animal test results on the highly infectious Delta variant first discovered in India....
...Biotech companies including Seegene, Celltrion Healthcare and Hyundai Bioscience as well as gaming groups such as Kakao Games have also been targeted by bearish investors....
...South Korean retail investors have piled into popular short targets in recent days including Celltrion, the healthcare company....
...Other companies in the Covid antibody field include Eli Lilly, GlaxoSmithKline and Celltrion....
...Rival Celltrion and Celltrion Healthcare have recorded similar gains over the same timeframe and are nearly as highly valued on earnings multiples....
...sales unit of another leading drugmaker, Celltrion, had violated accounting rules....
...Celltrion’s market cap reached Won36.3tn on Wednesday. Celltrion has become the darling of global investors, leading the biopharmaceutical rally in South Korea with its stock price doubling last year....
...Celltrion resumed its winning streak in 2018, climbing 55 per cent in the past two weeks, adding $12.4bn of equity value....
...A version of this article was first published by the Nikkei Asian Review on July 11, 2018. ©2018 Nikkei Inc. All rights reserved....
...Analysts estimate Celltrion Healthcare’s operating profit margins at over 20 per cent as the company is the exclusive marketer of Celltrion’s biological drugs....
...He cited South Korea-based Celltrion, whose biosimilar version of Herceptin was approved in Europe last year, along with companies he classes as “newcomers” to the field: Russian biotech BIOCAD, Japan’s...
...Celltrion is seeking US approval for the drug along with its partner Hospira, which is being bought by Pfizer....
...Its domestic competitor Celltrion, which launched a major arthritis biosimilar this year, has a market capitalisation of Won8.7tn — 82 times its forecast earnings this year....
...“Healthcare people said Celltrion was insane,” says Kim Hyun-tae, analyst at KDB Daewoo Securities....
...Chicago-based Hospira has been an early leader in the field, while South Korean companies are now establishing a strong foothold through both Celltrion and Samsung Bioepis....
...Celltrion of South Korea is pushing to secure regulatory approval for its Remicade copycat in the US....
...Coming deals include military systems developer LIG Nex1, budget carrier Jeju Air, Lotte Data Communication, SK Lubricants and Celltrion Healthcare....
...Celltrion of South Korea and Hospira of the US launched versions of Remicade in Europe last month....
...Celltrion is South Korea’s biggest maker of biosimilars – cheaper generic versions of complex biotechnology medicines....
...It also signals the growth of biosimilar drug producers from Asia, with the newly approved versions developed by Celltrion of South Korea, which in turn has licensed them to Hospira for use in Europe, North...
...Celltrion had to withstand years of expenditure without any visible sales....
...Seo Jung-jin, the chief executive of Celltrion, South Korea’s leading biopharmaceutical company, has made a strong career comeback....
...However, it highlighted that Celltrion, a South Korean company in partnership with Hospira, already has a biosimilar Herceptin for cancer under test, which it estimated could be launched in emerging markets...
...It plans to develop its nationwide properties this year and list its biotech unit Celltrion in the second half. It has also paid out substantial dividends ?...
International Edition